Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline

Abstract

A novel coronavirus (2019-nCoV) is an acute life-threatening disease, emerged in China, which imposed a potentially immense toll in terms of public health emergency due to high infection rate and has a devastating economic impact that attracts the world's attention. After that, on January 30, 2020, it was officially declared as a global pandemic by World Health Organization (WHO). The International Committee on Taxonomy of Viruses (ICTV) recognized it as a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and the disease named Coronavirus Disease-19 (COVID-19). Several studies have been ameliorated the active role of COVID-19 transmission, etiology, pathogenicity, and mortality rate as serious impact on human life. The symptoms of this disease may include fever, fatigue, cough and some peoples are severely prone to gastrointestinal infection. The elderly and seriously affected peoples are likely concerned with serious outcomes. In this review, we mainly aimed to provide a benchmark summary of the silent characteristics and findings of some candidates for antiviral drugs and immunotherapies such as plasma therapy, cytokine therapy, antibodies, intravenous immunoglobulin, and pharmaceutical health concerns that are related to this disease.

Keywords: COVID-19; Clinical characteristics; Diagnosis; Origin; Pharmaceutical services; SARS-CoV-2; Transmission.

Fig. 1

The critical role of diagnosing laboratory medicine in COVID-19.

Fig. 2

Schematic representation of systematic and respiratory disorders of COVID-19 patient.

Fig. 3

Pathogenesis of COVID-19. a) Coronavirus attacking the lungs. b) Coronavirus entry and replication inside the host’s cells. c) Antigen-presenting cell (APC) presenting the antigen to the surface of the T lymphocyte. d) Cytokine storm which causes multiple organ failure.